P
Paul J. Orchard
Researcher at University of Minnesota
Publications - 259
Citations - 14759
Paul J. Orchard is an academic researcher from University of Minnesota. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 48, co-authored 229 publications receiving 12985 citations. Previous affiliations of Paul J. Orchard include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Cellular Therapy in Rare Childhood Neurologic Disease: Lessons, Outcomes, and Access.
TL;DR: If sufficient benefit has not been demonstrated, transplants should only be performed for nonstandard indications in the setting of a clinical trial, preferentially a prospective, multi-institutional study to maximize patient numbers.
Journal ArticleDOI
Predictors of Long-Term Clinical Outcome in Hurler Syndrome Patients after Successful Hematopoietic Cell Transplantation: An International Study
Mieke Aldenhoven,Paul J. Orchard,Joanne Kurtzberg,Robert Wynn,Anne O'Meara,Paul Veys,Alain Fischer,Vassili Valayannopoulos,Bénédicte Neven,Attilio Rovelli,Vinod K. Prasad,Jakub Tolar,Elsa Shapiro,Simon Jones,Rossella Parini,Marleen Renard,Victoria Bordon,Michele D. Poe,Tom J. de Koning,Ed Wraith,Maria L. Escolar,Jaap-Jan Boelens +21 more
TL;DR: Although HCT significantly improved the clinical course in HS patients, residual disease burden was observed in the majority of transplanted HS patients and using exclusively non-carrier donors and accepting only full donor-chimerism will improve the prognosis of patients.
Journal ArticleDOI
Peripheral Blood Lymphoid and Myeloid Chimerism after Hematopoietic Stem Cell Transplant for Non-Malignant Disorders
Journal ArticleDOI
Exploring surrogate biomarkers of skeletal and joint disease progression in mucopolysaccharidosis type I
Lynda E. Polgreen,Jeremiah S Menk,Kyle Rudser,Ellen B. Fung,Bradley S. Miller,Klane K. White,Paul J. Orchard,Troy C. Lund +7 more
TL;DR: Once validated, these biomarkers may prove useful in determining early efficacy of skeletal or joint directed therapies in MPS I and are identified as potential candidate surrogate biomarkers of change in skeletal or Joint disease over time.